Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M759Revenue $M17.3Net Margin (%)-213.7Z-Score4.5
Enterprise Value $M657EPS $-0.6Operating Margin %-180.8F-Score6
P/E(ttm))0Cash Flow Per Share $-1.2Pre-tax Margin (%)-213.7Higher ROA y-yY
Price/Book6.910-y EBITDA Growth Rate %-7.6Quick Ratio3.1Cash flow > EarningsY
Price/Sales34.55-y EBITDA Growth Rate %7.3Current Ratio3.1Lower Leverage y-yY
Price/Cash Flow0y-y EBITDA Growth Rate %0ROA % (ttm)-58.4Higher Current Ratio y-yY
Dividend Yield %0Insider Buy (3m)0ROE % (ttm)-246.2Less Shares Outstanding y-yN
Payout Ratio %0Shares Outstanding M60.1ROI % (ttm)-126.5Gross Margin Increase y-yY

Gurus Latest Trades with BCRX

Number of guru portfolios checked: 56. (List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)
TickerGuruDate Action
Impactdown Price Range
(Average)*
Current Price Change from Average Comment Current Shares
BCRXGeorge Soros 2014-06-30 Sold Out -0.01%$7.37 - $12.52
($9.68)
$ 10.367%Sold Out0
BCRXGeorge Soros 2014-03-31 Buy 0.01%$7.6 - $12.83
($10.56)
$ 10.36-2%New holding, 59700 sh.59,700
Premium Real Time Picks are included for Premium Members only!!
*The price and date might not be the actual time and price at which the transactions were made. In the case of institutional owners, the date is stated as the last day of their fiscal quarter. The prices are estimates if no accurate information available. Foreign holdings may not be included.

BCRX is held by these Gurus:

Ticker Guru Name Portfolio Date* Current Shares % of Shares Outstanding % of Total Assets Managed Change from Last Holdings Holding History
BCRX George Soros 2014-06-30000Sold Out
Premium Most recent portfolio changes are included for Premium Members only!


BCRX: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
STAAB THOMAS R IISenior Vice President and CFO 2014-08-27Sell10,000$13.58-21.13view
STAAB THOMAS R IISenior Vice President and CFO 2014-07-01Sell3,125$13-17.62view
STAAB THOMAS R IISenior Vice President and CFO 2014-06-23Sell3,125$12.49-14.25view
STAAB THOMAS R IISenior Vice President and CFO 2014-06-17Sell3,125$12-10.75view
STAAB THOMAS R IISenior Vice President and CFO 2014-03-14Sell3,125$11.24-4.72view
LEE KENNETH B JRDirector 2014-03-06Sell12,665$12.69-15.6view
STAAB THOMAS R IISenior Vice President and CFO 2014-03-04Sell3,000$12.69-15.6view
Babu Yarlagadda SSenior VP - Drug Discovery 2014-03-04Sell40,642$12.57-14.8view
Barnes Alane PVP, General Counsel & Corp Sec 2014-03-04Sell40,734$12.63-15.2view
ABERCROMBIE GEORGE BDirector 2013-11-12Buy3,000$6.1973.02view

Press Releases about BCRX :

    Quarterly/Annual Reports about BCRX:

    News about bcrx:

    Articles On GuruFocus.com
    comment on BCRX Mar 02 2013 
    BioCryst Pharmaceuticals Inc. Reports Operating Results (10-K) Mar 15 2011 
    BioCryst Pharmaceuticals Inc. Reports Operating Results (10-K/A) Jan 19 2011 
    BioCryst Pharmaceuticals Inc. Reports Operating Results (10-Q) Nov 08 2010 
    BioCryst Pharmaceuticals Inc. Reports Operating Results (10-Q) Aug 06 2010 
    BioCryst Pharmaceuticals Inc. (BCRX) SR VP & CFO Stuart Grant sells 2,500 Shares Aug 06 2010 
    BioCryst Pharmaceuticals Inc. (BCRX) SR VP & CFO Stuart Grant sells 1,250 Shares Jun 04 2010 
    BioCryst Pharmaceuticals Inc. Reports Operating Results (10-Q) May 07 2010 
    BioCryst Pharmaceuticals Inc. (BCRX) SR VP & CFO Stuart Grant sells 1,250 Shares May 05 2010 
    BioCryst Pharmaceuticals Inc. (BCRX) SR VP & CFO Stuart Grant sells 38,553 Shares Apr 30 2010 


    More From Other Websites
    Nasdaq stocks posting largest percentage increases Sep 19 2014
    The Dire Need For A Rapid Diagnostic Ebola Test In West Africa Sep 18 2014
    BIOCRYST PHARMACEUTICALS INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Other... Sep 18 2014
    BioCryst Receives Additional NIAID Funding for Manufacture and Development of BCX4430 to Treat... Sep 18 2014
    [$$] Who Is Working on Ebola? Sep 18 2014
    Containing Ebola Outbreak Requires American Leadership Sep 16 2014
    Momentum Stocks Showing Weakness Sep 15 2014
    Gates Foundation Commits $50 Million To Ebola Containment Efforts Sep 10 2014
    Trade Ebola Stocks? Sure, But Don't Bet on Big Business Opportunity Sep 10 2014
    BioCryst Announces RAPIVAB(TM) Trial Results for the Treatment of Influenza at the ICAAC 2014... Sep 06 2014
    WHO Ebola Drug Panel: Use Survivor Serum To Treat Ebola Victims Sep 05 2014
    BioCryst Pharmaceuticals, Inc. Sinks; WHO Notes Ebola Safety Data Unavailable Sep 05 2014
    BioCryst Participates in World Health Organization Consultation on Potential Ebola Therapies Sep 04 2014
    BioCryst to Present at Rodman & Renshaw Conference Sep 03 2014
    BioCryst's Ebola Candidate Moving to Efficacy Study Soon Sep 02 2014
    BIOCRYST PHARMACEUTICALS INC Files SEC form 8-K, Regulation FD Disclosure Sep 02 2014
    BioCryst to Present Peramivir Trial Results for the Treatment of Influenza at the ICAAC 2014 Meeting Sep 02 2014
    BIOCRYST PHARMACEUTICALS INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Other... Aug 29 2014
    BioCryst to Launch NHP Ebola Drug Safety, Efficacy Studies 'Within Weeks' Aug 29 2014
    BioCryst Receives Additional NIAID Funding to Conduct a Non-Human Primate Study of BCX4430 in Ebola... Aug 29 2014

    Add Notes, Comments

    If you want to ask a question, or report a bug, please create a support ticket.

    User Comments

    No comment yet
    Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
    GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
    Free 7-day Trial
    FEEDBACK